By Sabrina Valle NEW YORK (Reuters) -Large deals involving pharmaceutical and biotech companies are stalling as executives ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

According to Direxion CEO Douglas Yones, Eli Lilly and Palo Alto Networks are prime candidates for leveraged trading.

Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

Insiders who purchased Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) shares in the past 12 months are unlikely to ...